Explore Treatments for Secondary Immune Deficiency Diseases

Secondary immunodeficiency diseases are a group of disorders where the immune system is weakened or compromised due to external factors, rather than being a result of a genetic defect. These factors can include infections, medications, and other medical conditions. Unlike primary immunodeficiencies, which are inherited, secondary immunodeficiencies are acquired after birth. Despite their differences, secondary immune deficiencies share a defect in how the immune system normally protects the body and the treatment depends on the severity of the deficiency in the immune system. Treatment of the underlying cause often leads to improvement of the condition and administration of immunoglobulins may also be useful.

Treatments Offered by CSI

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma is rigorously processed and purified to ensure product safety and integrity. Intravenous immunoglobulin (IVIG) contains antibodies that provide broad protection against a wide range of bacteria and viruses. It is administered intravenously and is primarily used to treat three categories of conditions: primary immunodeficiency diseases, autoimmune disorders, and certain neurological conditions. 

  • Alyglo 10% 
  • Asceniv 10% 
  • Bivigam 10% 
  • Gammagard S/D 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Gammaplex 5% 
  • Gammaplex 10% 
  • Octagam 5% 
  • Octagam 10% 
  • Panzyga 10% 
  • Privigen 10% 
  • Yimmugo 10%

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma undergoes rigorous processing and purification to ensure the highest standards of safety and product integrity. Subcutaneous immunoglobulin (SCIG) contains antibodies that offer broad protection against a wide range of bacteria and viruses. It is administered under the skin (subcutaneously) and is primarily used to treat primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy (CIDP). SCIG is also being studied in clinical trials for use in additional conditions. 

  • Cutaquig 16.5%  
  • Cuvitru 20% 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Hizentra 20% 
  • HyQvia 10% (facilitated SCIG)  
  • Xembify 20%